Publicacións nas que colabora con José Seijas Amigo (11)

2023

  1. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials

    The American journal of cardiology, Vol. 205, pp. 321-324

  2. Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study

    American Journal of Cardiovascular Drugs, Vol. 23, Núm. 5, pp. 583-593

  3. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

    Primary Care Diabetes, Vol. 17, Núm. 4, pp. 366-372

  4. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  5. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis

    Journal of cardiovascular pharmacology, Vol. 81, Núm. 1, pp. 70-75

2022

  1. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  2. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  3. Semaglutide versus GLP-1 agonists. Effectiveness, safety, and quality of life in patients with diabetes mellitus 2. The SEVERAL study

    Farmacia Hospitalaria, Vol. 46, Núm. 6, pp. 372-379

  4. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

2021

  1. Estudio observacional, multicéntrico y prospectivo para evaluar los cambios en la función cognitiva en pacientes tratados con iPCSK9. Protocolo de estudio

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 45, Núm. 3, pp. 150-154

2017

  1. La fracción de eyección intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca

    Revista Espanola de Cardiologia, Vol. 70, Núm. 5, pp. 338-346